News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Data on Odanacatib, Merck Sharp & Dohme (MRK)'s Investigational Cathepsin-K Inhibitor for Osteoporosis, Presented at Merck & Co., Inc. (MRK) Annual Meeting


10/19/2010 9:22:10 AM

TORONTO--(BUSINESS WIRE)--New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada. The data from clinical and preclinical studies, presented in two oral presentations and six posters, continue to provide further background on the potential of odanacatib to increase bone density, cortical thickness and bone strength when treating osteoporosis.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES